Overview
- The Praise-U pilot in Manresa and Ferrol applies a stepwise pathway that starts with PSA testing, performs an abdominal ultrasound to calculate prostate volume, uses PSA density thresholds to select men for MRI, and reserves biopsy for MRI-detected lesions.
- Fundació Althaia reported around 43% participation this weekend in its local pilot, showing initial feasibility but raising questions about MRI and biopsy capacity for wider rollout.
- Prostate cancer remains highly prevalent regionally with about 35,000 new cases in Spain, more than 13,300 in Argentina, and GLOBOCAN 2024 estimating 8,526 cases and 2,993 deaths in Peru.
- Experts stress selective screening because PSA is sensitive but non-specific, many detected tumors are low‑risk and managed with active surveillance, and broad screening risks overdiagnosis and unnecessary treatment.
- Scaling a selective pathway could lower unnecessary biopsies and overtreatment but will depend on MRI access, biopsy resources and efforts to overcome cultural barriers that drive late diagnosis, as shown by Peru's public system data reporting 75% of patients present with advanced disease.